Clinical Trial

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: * To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases * To determine the recommended dose for Phase 1b. * To evaluate the preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-22
notable Trial sites expanded: 0 -> 3 locations 2026-04-22
Trial Details
NCT Number NCT07304154
Lead Sponsor Kite, A Gilead Company
Conditions Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
Enrollment 52 participants
Start Date 2026-04-10
Primary Completion 2029-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-14